Norepinephrine
Catecholamine — CARDIOVASCULAR SYSTEM
Also known as: (-)-noradrenaline, (R)-Norepinephrine, arterenol, levarterenol, noradrenaline, norepinephrine bitartrate
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Norepinephrine is an ofp drug in the Catecholamine class catalogued in DrugCentral. It was first approved by the FDA in 1950. DrugCentral lists 27 molecular targets, including Adra2b|Adra2c|Adra2a, Adra1b|Adra2b|Adra2c|Adra2a|Adra1d|Adra1a and ADRA1D. Recorded indications include Acute exacerbation of asthma, Asthma, Asthma management and Bronchiectasis.
- Approval status: ofp (first approved 1950 by the FDA).
- Drug class: Catecholamine.
- Molecular targets: Adra2b|Adra2c|Adra2a, Adra1b|Adra2b|Adra2c|Adra2a|Adra1d|Adra1a, ADRA1D and ADRA2C (27 listed in DrugCentral).
- Indications: Acute exacerbation of asthma, Asthma, Asthma management, Bronchiectasis and Bronchitis and others.
- ATC code: C01CA03 (Adrenergic and dopaminergic agents).
- Molecular formula: C8H11NO3; molecular weight 169.18 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (7)
- Acute exacerbation of asthma
- Asthma
- Asthma management
- Bronchiectasis
- Bronchitis
- Low blood pressure
- Pulmonary emphysema
Contraindications (6)
- Hypercapnia
- Hypertensive disorder
- Hypovolemia
- Hypoxia
- Occlusive Vascular Disease
- Thrombosis
Mechanism & targets
| Established pharmacologic class | Catecholamine |
|---|
Molecular targets (27)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Adrenergic receptor alpha-2 | Adra2b|Adra2c|Adra2a | unknown | Ki 8.32 |
| Adrenergic receptor alpha | Adra1b|Adra2b|Adra2c|Adra2a|Adra1d|Adra1a | unknown | IC50 7.80 |
| Alpha-1D adrenergic receptor | ADRA1D | agonist | Ki 7.40 |
| Alpha-2C adrenergic receptor | ADRA2C | agonist | Ki 7.20 |
| Alpha-2A adrenergic receptor | ADRA2A | agonist | Ki 7.18 |
| Alpha-2B adrenergic receptor | Adra2b | unknown | Ki 7.11 |
| Beta-1 adrenergic receptor | Adrb1 | unknown | Ki 6.90 |
| Alpha-1B adrenergic receptor | ADRA1B | unknown | Ki 6.58 |
| Alpha-2B adrenergic receptor | ADRA2B | unknown | Ki 6.48 |
| Adrenergic receptor alpha-1 | Adra1b|Adra1d|Adra1a | unknown | Ki 6.41 |
| Beta-1 adrenergic receptor | ADRB1 | unknown | Ki 6.40 |
| Alpha-1A adrenergic receptor | ADRA1A | unknown | Ki 6.35 |
| Alpha-2C adrenergic receptor | Adra2c | unknown | Ki 6.19 |
| Adrenergic receptor beta | Adrb2|Adrb1|Adrb3 | unknown | IC50 6.00 |
| Beta-1 adrenergic receptor | ADRB1 | agonist | Ki 6.00 |
| D(2) dopamine receptor | DRD2 | unknown | Ki 5.89 |
| Alpha-1A adrenergic receptor | ADRA1A | agonist | Ki 5.82 |
| Beta-2 adrenergic receptor | ADRB2 | agonist | Kd 5.40 |
| Beta-2 adrenergic receptor | Adrb2 | unknown | Ki 5.38 |
| Beta-3 adrenergic receptor | ADRB3 | unknown | Ki 5.37 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1950-07-13 | FDA | — | HOSPIRA |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
C01CA03 | CARDIOVASCULAR SYSTEM › CARDIAC THERAPY › CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES › Adrenergic and dopaminergic agents |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Multiple organ dysfunction syndrome | 1518.3 |
| Drug ineffective | 1165.6 |
| Cardiogenic shock | 1009.1 |
| Appendicolith | 659.3 |
| Cardiac arrest | 634.0 |
| Septic shock | 622.8 |
| Shock | 528.0 |
| Ventricular fibrillation | 511.0 |
| Appendicitis | 500.0 |
| Hypotension | 490.5 |
| Acute kidney injury | 471.7 |
| Metabolic acidosis | 455.8 |
Chemical structure
| Molecular formula | C8H11NO3 |
|---|---|
| Molecular weight | 169.18 g/mol |
| CAS number | — |
| InChIKey | SFLSHLFXELFNJZ-QMMMGPOBSA-N |
| PubChem CID | 439260 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Norepinephrine used for?
DrugCentral lists the following indications for Norepinephrine: Acute exacerbation of asthma, Asthma, Asthma management, Bronchiectasis, Bronchitis, Low blood pressure and Pulmonary emphysema.
How does Norepinephrine work?
Its molecular targets in DrugCentral include Adra2b|Adra2c|Adra2a, Adra1b|Adra2b|Adra2c|Adra2a|Adra1d|Adra1a, ADRA1D (agonist) and ADRA2C (agonist).
When was Norepinephrine first approved?
Norepinephrine was first approved by the FDA in 1950.
What drug class does Norepinephrine belong to?
Norepinephrine is in the Catecholamine class.
What is the chemical formula of Norepinephrine?
Norepinephrine has the molecular formula C8H11NO3 and a molecular weight of 169.18 g/mol.
Browse: all drugs starting with N · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 1960 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1434513 — compound record and bioactivity
- PubChem CID 439260 — chemical identifiers
- DrugBank DB00368 — drug record
- FDA UNII IFY5PE3ZRW — substance identity
- DailyMed: FDA labels for Norepinephrine — current prescribing information (label search)
- UniProt P25100 (ADRA1D) — target protein
- UniProt P18825 (ADRA2C) — target protein
- UniProt P08913 (ADRA2A) — target protein
- UniProt P18089 (ADRA2B) — target protein
- UniProt P08588 (ADRB1) — target protein
- UniProt P14416 (DRD2) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.